IntroductionProgrammed cell death protein 1 (PD-1) and its ligand, PD-L1, are crucial immune checkpoints that regulate the ...

在过去几十年里，诸如检查点抑制剂疗法等免疫疗法通过训练机体免疫系统来攻击癌症，彻底改变了癌症的治疗；然而，这些疗法通常在实体瘤治疗中效果不佳，在实体瘤中，敌对的肿瘤微环境（TME）阻碍了免疫细胞的活性，比如，在诸如 胰腺癌 ...

Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will ...

Here authors show that via combining radiotherapy, PARP inhibitors and anti-PD-L1 treatments, T cell infiltration and function could be improved via mechanisms that increase the chemo-attractants ...

Researchers from the VIB-KU Leuven Center for Cancer Biology, in collaboration with other scientists, have discovered a way ...

About PD-1 Inhibitors PD-1 inhibitors work by blocking the PD-1 (programmed death-1) receptor on T cells, preventing cancer cells from evading the immune system and restoring the body’s ability to ...

Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...

Our blood consists of many cell types that develop through different stages from a precursor type—the blood stem cell. An ...

A new research paper was published in Oncotarget's Volume 16 on January 20, 2025, titled "Anti-correlation of KLRG1 and PD-1 ...